1. Home
  2. KMDA vs EOLS Comparison

KMDA vs EOLS Comparison

Compare KMDA & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kamada Ltd.

KMDA

Kamada Ltd.

HOLD

Current Price

$6.97

Market Cap

385.3M

Sector

Health Care

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$6.59

Market Cap

444.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMDA
EOLS
Founded
1990
2012
Country
Israel
United States
Employees
374
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
385.3M
444.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
KMDA
EOLS
Price
$6.97
$6.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$13.00
$21.25
AVG Volume (30 Days)
66.9K
1.8M
Earning Date
11-10-2025
11-05-2025
Dividend Yield
2.96%
N/A
EPS Growth
30.41
N/A
EPS
0.35
N/A
Revenue
$174,787,000.00
$285,823,000.00
Revenue This Year
$14.49
$13.39
Revenue Next Year
$10.12
$26.85
P/E Ratio
$19.14
N/A
Revenue Growth
10.36
15.10
52 Week Low
$5.54
$5.71
52 Week High
$9.16
$17.12

Technical Indicators

Market Signals
Indicator
KMDA
EOLS
Relative Strength Index (RSI) 53.31 45.09
Support Level $6.70 $6.53
Resistance Level $6.83 $7.15
Average True Range (ATR) 0.16 0.33
MACD -0.01 -0.03
Stochastic Oscillator 47.65 6.17

Price Performance

Historical Comparison
KMDA
EOLS

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: